Astellas Pharma Inc.
ALPMF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $1,912,323 | $1,603,672 | $1,518,619 | $1,296,163 |
| % Growth | 19.2% | 5.6% | 17.2% | – |
| Cost of Goods Sold | $349,206 | $292,485 | $288,353 | $253,009 |
| Gross Profit | $1,563,117 | $1,311,187 | $1,230,266 | $1,043,154 |
| % Margin | 81.7% | 81.8% | 81% | 80.5% |
| R&D Expenses | $327,651 | $294,200 | $276,128 | $246,010 |
| G&A Expenses | $843,032 | $740,110 | $630,272 | $548,840 |
| SG&A Expenses | $843,032 | $740,110 | $630,272 | $548,840 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $351,395 | $251,359 | $38,436 | $28,283 |
| Operating Expenses | $1,522,078 | $1,285,669 | $944,836 | $823,133 |
| Operating Income | $41,039 | $25,518 | $133,029 | $220,021 |
| % Margin | 2.1% | 1.6% | 8.8% | 17% |
| Other Income/Exp. Net | -$9,802 | -$549 | -$668 | -$63,135 |
| Pre-Tax Income | $31,237 | $24,969 | $132,361 | $156,886 |
| Tax Expense | -$19,510 | $7,924 | $33,647 | $32,800 |
| Net Income | $50,747 | $17,045 | $98,714 | $124,086 |
| % Margin | 2.7% | 1.1% | 6.5% | 9.6% |
| EPS | 28.35 | 9.5 | 54.24 | 67.08 |
| % Growth | 198.4% | -82.5% | -19.1% | – |
| EPS Diluted | 28.24 | 9.47 | 54.09 | 67.05 |
| Weighted Avg Shares Out | 1,797 | 1,793 | 1,820 | 1,850 |
| Weighted Avg Shares Out Dil | 1,797 | 1,800 | 1,825 | 1,851 |
| Supplemental Information | – | – | – | – |
| Interest Income | $7,874 | $11,455 | $8,110 | $6,149 |
| Interest Expense | $17,677 | $12,005 | $8,779 | $4,949 |
| Depreciation & Amortization | $199,132 | $157,840 | $105,738 | $79,684 |
| EBITDA | $248,046 | $194,814 | $337,390 | $297,829 |
| % Margin | 13% | 12.1% | 22.2% | 23% |